Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 1
1981 1
1984 1
1988 1
2004 1
2005 5
2006 2
2007 3
2008 6
2009 5
2010 3
2011 4
2012 4
2013 4
2014 3
2015 8
2016 5
2017 7
2018 10
2019 12
2020 18
2021 22
2022 21
2023 15
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
A Multi-Criteria Framework for Pandemic Response Measures.
Ekenberg L, Mihai A, Fasth T, Komendantova N, Danielson M. Ekenberg L, et al. Among authors: mihai a. Front Public Health. 2021 Apr 20;9:583706. doi: 10.3389/fpubh.2021.583706. eCollection 2021. Front Public Health. 2021. PMID: 33968871 Free PMC article.
The Effect of Topical Celecoxib as an Anti-Psoriasis Agent.
Nitescu DA, Paunescu H, Gologan D, Mihai A, Stoian AC, Coman OA. Nitescu DA, et al. Among authors: mihai a. Maedica (Bucur). 2022 Dec;17(4):805-811. doi: 10.26574/maedica.2022.17.4.805. Maedica (Bucur). 2022. PMID: 36818260 Free PMC article.
The ALPK1/TIFA/NF-κB axis links a bacterial carcinogen to R-loop-induced replication stress.
Bauer M, Nascakova Z, Mihai AI, Cheng PF, Levesque MP, Lampart S, Hurwitz R, Pfannkuch L, Dobrovolna J, Jacobs M, Bartfeld S, Dohlman A, Shen X, Gall AA, Salama NR, Töpfer A, Weber A, Meyer TF, Janscak P, Müller A. Bauer M, et al. Among authors: mihai ai. Nat Commun. 2020 Oct 9;11(1):5117. doi: 10.1038/s41467-020-18857-z. Nat Commun. 2020. PMID: 33037203 Free PMC article.
Dyselectrolytemia-management and implications in hemodialysis (Review).
Timofte D, Tanasescu MD, Balcangiu-Stroescu AE, Balan DG, Tulin A, Stiru O, Vacaroiu IA, Mihai A, Constantin PC, Cosconel CI, Enyedi M, Miricescu D, Ionescu D. Timofte D, et al. Among authors: mihai a. Exp Ther Med. 2021 Jan;21(1):102. doi: 10.3892/etm.2020.9534. Epub 2020 Nov 26. Exp Ther Med. 2021. PMID: 33363613 Free PMC article. Review.
159 results